Sitravatinib (MGCD516) is an experimental drug for the treatment of cancer. It is a small molecule inhibitor of multiple tyrosine kinases.
Sitravatinib is being developed by Mirati Therapeutics.
Ongoing phase II trials include a trial for liposarcoma, a combination trial for non-small cell lung cancer, and a combination trial with nivolumab for renal cell carcinoma. Sitravatinib is being evaluated in ongoing trials in patients with advanced non-small cell lung cancer, including in a combination trial with nivolumab in those who are resistant to checkpoint inhibitor therapy, and certain patients who are naïve to checkpoint inhibitor therapy.
References
Yang Y, Ji N, Cai CY, Wang JQ, Lei ZN, Teng QX, Wu ZX, Cui Q, Pan Y, Chen ZS (July 2020). "Modulating the function of ABCB1: in vitro and in vivo characterization of sitravatinib, a tyrosine kinase inhibitor". Cancer Communications. 40 (7): 285–300. doi:10.1002/cac2.12040. PMC 7365458. PMID 32525624. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7365458 ↩
"Sitravatinib | Mirati Therapeutics, Inc". http://www.mirati.com/go/mgcd516/ ↩
Clinical trial number NCT02978859 for "MGCD516 in Advanced Liposarcoma and Other Soft Tissue Sarcomas" at ClinicalTrials.gov https://www.clinicaltrials.gov/show/NCT02978859 ↩
Clinical trial number NCT02954991 for "Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung Cancer" at ClinicalTrials.gov https://www.clinicaltrials.gov/show/NCT02954991 ↩
Clinical trial number NCT03015740 for "MGCD516 Combined With Nivolumab in Renal Cell Cancer (RCC)" at ClinicalTrials.gov https://www.clinicaltrials.gov/show/NCT03015740 ↩
"A Randomized Phase 3 Study of Sitravatinib in Combination with Nivolumab Versus Docetaxel in Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer with Disease Progression on or After Platinum-Based Chemotherapy and Checkpoint Inhibitor Therapy SAPPHIRE". 28 February 2022. https://clinicaltrials.gov/ct2/show/NCT03906071 ↩